Please try another search
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich’s ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Name | Age | Since | Title |
---|---|---|---|
Paula H. J. Cholmondeley | 77 | 2021 | Independent Director |
Mette Kirstine Agger | 60 | 2020 | Independent Director |
Bernard Davitian | 64 | 2020 | Independent Director |
Kiran Musunuru | - | 2022 | Member of Scientific Advisory Board |
Brenda G. Cooperstone | 59 | 2023 | Independent Director |
Jeffery D. Molkentin | - | 2022 | Member of Scientific Advisory Board |
Victoria Parikh | - | 2022 | Member of Scientific Advisory Board |
Marianna Fontana | - | 2022 | Member of Scientific Advisory Board |
Iacopo Olivotto | - | 2022 | Member of Scientific Advisory Board |
Reinaldo M. Diaz | 70 | 2022 | Independent Director |
Eugene W. Yeo | 47 | 2022 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review